| All patients (N=271) | CD133 IHC expression (0) | CD133 IHC expression (1-10%) | CD133 IHC expression (11-50%) | CD133 IHC expression (51-100%) |
---|---|---|---|---|---|
Variables | N | % | % | % | % |
Gender | Â | Â | Â | Â | Â |
Male | 161 | 27.95 | 23.60 | 22.98 | 25.46 |
Female | 110 | 32.72 | 20.00 | 20.00 | 27.27 |
Tumor site* | Â | Â | Â | Â | Â |
Colon | 150 | 37.33 | 22.66 | 17.33 | 17.33 |
Rectum | 121 | 20.66 | 21.48 | 27.27 | 30.57 |
pTNM stage | Â | Â | Â | Â | Â |
II | 122 | 31.14 | 25.40 | 22.13 | 21.31 |
III | 149 | 28.85 | 19.46 | 21.47 | 30.20 |
pT stage | Â | Â | Â | Â | Â |
T1 | 4 | 75.00 | 0 | 0 | 25.00 |
T2 | 6 | 16.66 | 66.66 | 16.66 | 0 |
T3 | 239 | 29.70 | 21.75 | 22.17 | 26.35 |
T4 | 22 | 27.27 | 18.18 | 22.72 | 31.81 |
pN stage | Â | Â | Â | Â | Â |
N0 | 123 | 30.90 | 25.20 | 21.95 | 21.95 |
N1 | 88 | 29.54 | 17.04 | 25.00 | 28.40 |
N2 | 56 | 26.78 | 25.00 | 17.85 | 30.35 |
N3 | 4 | 50.00 | 0 | 0 | 50.00 |
Histologic differentiation* | Â | Â | Â | Â | Â |
Well | 16 | 37.50 | 31.25 | 18.57 | 12.50 |
Moderate | 225 | 25.33 | 22.22 | 22.66 | 29.77 |
Poor | 15 | 53.33 | 20 | 26.66 | 0 |
Mucinous adenocarcinoma | 15 | 66.66 | 13.33 | 6.66 | 13.33 |
Adjuvant therapy | Â | Â | Â | Â | Â |
Yes | 171 | 28.07 | 22.22 | 18.71 | 30.99 |
No | 100 | 33.00 | 22.00 | 27.00 | 18.00 |